Free Trial

Eliem Therapeutics Q1 2023 Earnings Report

Eliem Therapeutics logo
$2.34 -0.08 (-3.31%)
(As of 12/17/2024 ET)

Eliem Therapeutics EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.56
One Year Ago EPS
N/A

Eliem Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eliem Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A
Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

Eliem Therapeutics Earnings Headlines

Forbes rich list released… #1 to be assassinated?
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
See More Eliem Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email.

About Eliem Therapeutics

Eliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

View Eliem Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings